Top

Published in:

Open Access 01-12-2017 | Research

Plasma levels of MMP-7 and TIMP-1 in laboratory diagnostics and differentiation of selected histological types of epithelial ovarian cancers

Authors: Grażyna Ewa Będkowska, Ewa Gacuta, Monika Zajkowska, Edyta Katarzyna Głażewska, Joanna Osada, Maciej Szmitkowski, Lech Chrostek, Milena Dąbrowska, Sławomir Ławicki

Published in: Journal of Ovarian Research | Issue 1/2017

Abstract

Background

MMP-7 and TIMP-1 may play a role in the pathogenesis of cancer disease. In this study we investigated plasma levels of selected metalloproteinase and its tissue inhibitor in comparison to plasma levels of the commonly accepted tumor markers (CA 125 and HE4) in selected histological types of epithelial ovarian cancer patients as compared to control groups: patients with a benign ovarian tumor and healthy subjects. Plasma levels of MMP-7 and TIMP-1 were determined using ELISA, CA 125 and HE4 – by CMIA methods.

Results

Plasma levels of all biomarkers studied were significantly higher in ovarian cancer patients as compared to both control groups. MMP-7 demonstrated comparable to HE4 or CA125 values of diagnostic sensitivity (SE: 61%; 68%; 58%, respectively), specificity (SP: 95%; 95%; 98%, respectively), positive (PPV: 93%; 96%; 98%, respectively) and negative predictive values (NPV: 61%; 66%; 60%, respectively) in the groups tested. The combined use of the aforementioned biomarkers resulted in a further increase in diagnostic criteria and AUC, especially in the early stages of the disease.

Conclusions

These findings suggest the usefulness of combining MMP-7 with CA 125 and HE4 in the diagnosis of epithelial ovarian cancer as a new tumor marker panel.

Available only for authorised users

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;6:69–90.CrossRef

Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61:212–6.CrossRefPubMed

Vergote I, Banerjee S, Gerdes AM, van Asperen C, Marth C, Vaz F. Current perspectives on recommendations for BRCA genetic testing in ovarian cancer patients. Eur J Cancer. 2016;69:127–34.CrossRefPubMed

Xu K, Yang S, Zhao Y. Prognostic significance of BRCA mutations in ovarian cancer: an updated systematic review with meta-analysis. Oncotarget. 2017;8:285–302.PubMed

Molina R, Escudero JM, Auge JM, Filella X, Foj L, Torne A, et al. HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases. Tumor Biol. 2011;32:1087–95.CrossRef

Urban A, Miszczyk L. Ovarian cancer – diagnostical and therapeutical dilema in oncological gynecology. Wspol Onkol. 2003;7:294–300.

Schummer M, Drescher C, Forrest R, Gough S, Thorpe J, Hellstrom I, et al. Evaluation of ovarian cancer remission markers HE4, MMP7 and mesothelin by comparison to the established marker CA125. Gynecol Oncol. 2012;125:65–9.CrossRefPubMed

Chan KKL, Chen CA, Nam JH, Ochiai K, Wilailak S, Choon AT, et al. The use of HE4 in the prediction of ovarian cancer in Asian women with a pelvic mass. Gynecol Oncol. 2013;128:239–44.CrossRefPubMed

Drapkin R, von Horsten HH, Lin Y, Mok SC, Crum CP, Welch WR, et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res. 2005;65:2162–9.CrossRefPubMed

10.

Galgano MT, Hampton GM, Frierson HF Jr. Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol. 2006;19:847–53.PubMed

11.

Jiang SW, Chen H, Dowdy S, Fu A, Attewell J, Kalogera E, et al. HE4 transcription and splice variants-specific expression in endometrial cancer and correlation with patient survival. Int J Mol Sci. 2013;14:22655–77.CrossRefPubMedPubMedCentral

12.

Moore RG, Miller MC, Steinhoff MM, Skates SJ, Lu KH, Lambert-Messerlian G, et al. Serum HE4 levels are less frequently elevated than CA 125 in women with benign gynecologic disorders. Am J Obstet Gynecol. 2012;206:351.e1–8.

13.

Ławicki S, Gacuta-Szumarska E, Będkowska GE, Szmitkowski M. Hematopoietic cytokines as tumor markers in gynecological malignancies. A multivariate analysis in epithelial ovarian cancer patients. Growth Factors. 2012;30:357–66.CrossRefPubMed

14.

Candido dos Reis FJ, Moreira de Andrade J, Bighetti S. CA 125 and vascular endothelial growth factor in the differential diagnosis of epithelial ovarian tumors. Gynecol Obstet Invest. 2002;54:132–6.CrossRefPubMed

15.

Behrens P, Rothe M, Florin A, Wellman A, Wernert N. Invasive properties of serous human epithelial ovarian tumors are related to Ets-1, MMP-1 and MMP-9 expression. Int J Mol Med. 2001;8:149–54.PubMed

16.

Hu X, Li D, Zhang W, Zhou J, Tang B, Li L. Matrix metalloproteinase-9 expression correlates with prognosis and involved in ovarian cancer cells invasion. Arch Gynecol&Obstet. 2012;286:1537–43.

17.

Stamenkovic I. Extracellular matrix remodeling: the role of matrix metalloproteinases. J Pathol. 2003;200:448–64.CrossRefPubMed

18.

Worley JR, Thompkins PB, Lee MH, Hutton M, Soloway P, Edwards DR, et al. Sequence motifs of tissue inhibitor of metalloproteinases 2 (TIMP-2) determining progelatinase a (proMMP-2) binding and activation by membrane-type metalloproteinase 1 (MT1-MMP). Biochem J. 2003;372:799–809.CrossRefPubMedPubMedCentral

19.

Shiomi T, Okada Y. MT1-MMP and MMP-7 in invasion and metastasis of human cancers. Cancer Metastasis Rev. 2003;22:145–52.CrossRefPubMed

20.

Yin H, Sheng Z, Zhang X, Du Y, Qin C, Liu H, et al. Overexpression of SOX18 promotes prostate cancer progression via the regulation of TCF1, c-Myc, cyclin D1 and MMP-7. Oncol Rep. 2017;37:1045–51.PubMed

21.

Xiao XY, Lang XP. Correlation between MMP-7 and bFGF expressions in non-small cell lung cancer tissue and Clinicopathologic features. Cell Biochem Biophys. 2015;73:427–32.CrossRefPubMed

22.

Niedworok C, vom Dorp F, Tschirdewahn S, Rübben H, Reis H, Szucs M, et al. Validation of the diagnostic and prognostic relevance of serum MMP-7 levels in renal cell cancer by using a novel automated fluorescent immunoassay method. Int Urol Nephrol. 2016;48:355–61.CrossRefPubMed

23.

Xing XJ, Gu XH, Ma TF. Relationship of serum MMP-7 levels for colorectal cancer: a meta analysis. Tumour Biol. 2014;35:10515–22.CrossRefPubMed

24.

Yari K, Rahimi Z, Payandeh M, Rahimi Z. MMP-7 A-181G polymorphism in breast cancer patients from western Iran. Breast Care (Basel). 2015;10:398–402.CrossRef

25.

Christensen IJ, Brünner N, Dowell B, Davis G, Nielsen HJ, Newstead G, et al. Plasma TIMP-1 and CEA as markers for detection of primary colorectal cancer: a prospective validation study including symptomatic and non-symptomatic individuals. Anticancer Res. 2015;35:4935–41.PubMed

26.

Gong Y, Chippada-Venkata UD, Galsky MD, Huang J, Oh WK. Elevated circulating tissue inhibitor of metalloproteinase 1 (TIMP-1) levels are associated with neuroendocrine differentiation in castration resistant prostate cancer. Prostate. 2015;75:616–27.CrossRefPubMed

27.

Jenkinson C, Elliott V, Menon U, Apostolidou S, Fourkala OE, Gentry-Maharaj A. Evaluation in pre-diagnosis samples discounts ICAM-1 and TIMP-1 as biomarkers for earlier diagnosis of pancreatic cancer. J Proteome. 2015;113:400–2.CrossRef

28.

Ławicki S, Będkowska GE, Gacuta-Szumarska E, Szmitkowski M. The plasma concentration of VEGF, HE4 and CA125 as a new biomarkers panel in different stages and sub-types of epithelial ovarian tumors. J Ovarian Res. 2013;6:45–55.CrossRefPubMedPubMedCentral

29.

Hamed EO, Ahmed H, Sedeek OB, Mohammed AM, Abd-Alla AA, Abdel Ghaffar HM. Significance of HE4 estimation in comparison with CA 125 in diagnosis of ovarian cancer and assessment of treatment response. Diagn Pathol. 2013;8:s11.CrossRef

30.

Ruggeri G, Bandiera E, Zanotti L, Belloni S, Ravaggi A, Romani C, et al. HE4 and epithelial ovarian cancer: comparison and clinical evaluation of two immunoassays and a combination algorithm. Clin Chim Acta. 2011;412:1447–53.CrossRefPubMed

31.

Acar A, Onan A, Coskun U, Uner A, Bagriacik U, Atalay F, et al. Clinical significance of serum MMP-2 and MMP-7 in patients with ovarian cancer. Med Oncol. 2008;25:279–83.CrossRefPubMed

32.

Kren L, Goncharuk VN, Krenova Z, Stratil D, Hermanova M, Skrickova J, et al. Expression of matrix metalloproteinases 3, 10 and 11 (stromelysins 1,2 and 3) and matrix metalloproteinase 7 (matrilysin) by cancer cells in non-small cell lung neoplasms. Clinicopathologic studies Cesk Patol. 2006;42:16–9.PubMed

33.

Sier CF, Hawinkels LJ, Zijlmans HJ, Zuidwijk K, de Jonge-Muller ES, Ferreira V. Endothelium specific matrilysin (MMP-7) expression in human cancers. Matrix Biol. 2008;27:267–71.PubMed

34.

Sica GS, Fiorani C, Stolfi C, Monteleone G, Candi E, Amelio I, et al. Peritoneal expression of matrilysin helps identify early post-operative recurrence of colorectal cancer. Oncotarget. 2015;6:13402–15.CrossRefPubMedPubMedCentral

35.

Koskensalo S, Mrena J, Wiksten JP, Nordling S, Kokkola A, Hagstrom J, et al. MMP-7 overexpression is an independent prognostic marker in gastric cancer. Tumor Biol. 2010;31:149–55.CrossRef

36.

Määttä M, Talvensaari-Mattila A, Turpeenniemi-Hujanen T, Santala M. Matrix metalloproteinase-2 (MMP-2) and −9 (MMP-9) and their tissue inhibitors (TIMP-1 and TIMP-2) in differential diagnosis between low malignant potential (LMP) and malignant ovarian tumours. Anticancer Res. 2007;27:2753–8.PubMed

37.

Wu Z-S, Wu Q, Yang J-H, Wang H-Q, Ding X-D, Yang F, et al. Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer. Int J Cancer. 2008;122:2050–6.CrossRefPubMed

38.

Holten-Andersen L, Christensen IJ, Jensen SB, Reibel J, Laurberg S. Nauntofte bet al. Saliva and plasma TIMP-1 in patients with colorectal cancer: a prospective study. Scand J Gastroenterol. 2012;47:1234–41.CrossRefPubMed

39.

Ławicki S, Zajkowska M, Głażewska EK, Będkowska GE, Szmitkowski M. Plasma levels and diagnostic utility of VEGF, MMP-9, and TIMP-1 in the diagnosis of patients with breast cancer. Onco Targets Ther. 2016;9:911–9.PubMedPubMedCentral

40.

Ławicki S, Głażewska EK, Sobolewska M, Będkowska GE, Szmitkowski M. Plasma levels and diagnostic utility of macrophage colony-stimulating factor, matrix metalloproteinase-9, and tissue inhibitor of metalloproteinases-1 as a new biomarkers of breast cancer. Ann Lab Med. 2016;36:223–9.CrossRefPubMedPubMedCentral

41.

Zheng H, Gao Y. Serum HE4 as a useful biomarker in discriminating ovarian cancer from benign pelvic disease. Int J Gynecol Cancer. 2012;22:1000–5.CrossRefPubMed

42.

Beeghly-Faidel A, Xiang Y-B, Deming SL, Long JR, Xu W-H, Cai Q, et al. No association between matrix metalloproteinase (MMP)-1, −3, and −7 SNPs and endometrial cancer risk. Cancer Epidemiol Biomark Prev. 2009;18:1925–8.CrossRef

43.

Będkowska GE, Ławicki S, Gacuta E, Pawłowski P, Szmitkowski M. M-CSF in a new biomarker panel with HE4 and CA125 in the diagnostics of epithelial ovarian cancer patients. J Ovarian Res. 2015;8:27–38.CrossRefPubMedPubMedCentral

44.

Park Y, Lee J-H, Hong DJ, Lee EY, Kim H-S. Diagnostic performances of HE4 and CA 125 for the detection of ovarian cancer from patients with various gynecologic and non-gynecologic diseases. Clin Biochem. 2011;44:884–8.CrossRefPubMed

45.

Azzam AZ, Hashad DI, Kamel NA. Evaluation of HE4 as an extrabiomarker to CA 125 to improve detection of ovarian carcinoma: is it time for a step forward? Arch Gynecol Obstet. 2013;288:167–72.CrossRefPubMed

46.

Zohny SF, Fayed ST. Clinical utility of circulating matrix metalloproteinase-7 (MMP-7), CC chemokine ligand 18 (CCL 18) and CC chemokine ligand 11 (CCL 11) as a markers for diagnosis of epithelial ovarian cancer. Med Oncol. 2010;27:1246–53.CrossRefPubMed

47.

Ławicki S, Będkowska GE, Gacuta-Szumarska E, Knapp P, Szmitkowski M. Pretreatment plasma levels and diagnostic utility of hematopoietic cytokines in cervical cancer or cervical intraepithelial neoplasia patients. Folia Histochem Cytobiol. 2012;50:213–9.CrossRefPubMed

48.

Ławicki S, Będkowska GE, Gacuta-Szumarska E, Szmitkowski M. Hematopoietic cytokines as tumor markers in gynecological malignancies: a multivariate analysis with ROC curve in endometrial cancer patients. Growth Factors. 2012;30:29–36.CrossRefPubMed

49.

Fawzy A, Mohamed MR, Ali MA, Abd El-Magied MH, Helal AM. Tissues CA125 and HE4 gene expression levels offer superior accuracy in discriminating benign from malignant pelvic masses. Asian Pac J Cancer Prev. 2016;17:323–33.CrossRefPubMed

Title: Plasma levels of MMP-7 and TIMP-1 in laboratory diagnostics and differentiation of selected histological types of epithelial ovarian cancers
Authors: Grażyna Ewa Będkowska
Ewa Gacuta
Monika Zajkowska
Edyta Katarzyna Głażewska
Joanna Osada
Maciej Szmitkowski
Lech Chrostek
Milena Dąbrowska
Sławomir Ławicki
Publication date: 01-12-2017
Publisher: BioMed Central
Published in: Journal of Ovarian Research / Issue 1/2017
Electronic ISSN: 1757-2215
DOI: https://doi.org/10.1186/s13048-017-0338-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Plasma levels of MMP-7 and TIMP-1 in laboratory diagnostics and differentiation of selected histological types of epithelial ovarian cancers

Abstract

Background

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2017

Does the transfer of a poor quality embryo together with a good quality embryo affect the In Vitro Fertilization (IVF) outcome?

Follicular Fluid redox involvement for ovarian follicle growth

HBXIP overexpression is correlated with the clinical features and survival outcome of ovarian cancer

Evidence of metachronous development of ovarian teratomas: a case report of bilateral mature cystic teratomas of the ovaries and systematic literature review

Anatomical organization and neural pathways of the ovarian plexus nerve in rats

MicroRNA-205 promotes cell invasion by repressing TCF21 in human ovarian cancer